Denali Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 19.32 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.09B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzym...